E fisiopatologia di kanser di próstata ta referí na e mekanismonan i prosesonan ku ta kondusí na desaroyo i progreso di e malesa.
Kanser di próstata ta un tumor maligno ku ta surgi for di e sèlnan di e glándula di próstata, ku ta un órgano chikitu ku forma di un nuez ku ta keda bou di e wesunan di hende hòmber.
E glándula di próstata ta produsí suku ku ta alimentá i transportá e sperma.
E kousa eksakto di kanser di próstata no ta kompletamente komprondé, pero ta konosí ku tin diferente faktor ku ta oumentá e riesgo di desaroyá e malesa.
Esakinan ta inkluí edat, historia familiar, rasa i sierto mutashon genétiko.
Kanser di prostaat ta mas komun serka hòmbernan di mas edat, mayoria di e kasonan ta tuma lugá serka hòmbernan di mas ku 65 aña.
Ademas, hòmbernan ku tin antecedente di kanser di próstata den nan famia ta kore mas riesgo, meskos ku hòmbernan afro-merikano i di desendensia karibense.
E fisiopatologia di kanser di próstata ta enserá kresementu i divishon di sèlnan den e glándula di próstata.
Esaki por sosodé pa motibu di mutashonnan genétiko ku ta kondusí na ekspresion di sierto faktornan di kresementu òf inaktivo di genes suppressor di tumor.
E mutashonnan aki por resultá den kresementu desreglá di sèlnan, ku ta kondusí na formashon di un tumor.
Ora e tumor krese, e por invadi e tehidonan i órganonan den bisindario, manera e blènder, e retto i e ganglionnan limfátiko den bisindario.
Den algun kaso, e sèlnan di kanser por separá for di e tumor primario i plama na otro parti di kurpa via e sistema di sanger òf sistema limfatiko, un proseso konosí komo metástasis.
Unabes e kanser a plama, e por ta mas difísil pa trata.
Kanser di prostaat tambe por ta influensiá pa faktornan hormonal, partikularmente e hormona andrógeno testosterona.
Testosteron por stimulá kresementu di sèlnan di kanser di próstata, i hopi tratamentu pa kanser di próstata tin komo meta redusí e nivel di e hormona akí òf blòkia su efekto.
En resumen, e fisiopatologia di kanser di próstata ta enbolbí kresementu i divishon di sèlnan den e glándula di próstata, ku por ta influensiá pa faktornan genétiko, hormonal i ambiental.
Komprondé e mekanismo di e malesa ta krusial pa desaroyá tratamentunan efektivo i mehorá resultado pa pashèntnan ku kanser di próstata.
Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.
Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.
Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.
Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.
Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.
Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.
['Disclaimer: médiko']
['E website aki ta pa informashon i edukashon so i no ta pa duna konseho médiko òf servisio profeshonal.']
['E informashon ku ta ser duná no mester ser usá pa diagnostiká òf trata un problema di salú òf malesa, i esnan ku ta buska konseho médiko personal mester konsultá ku un dòkter ku tin un pèrmit di traha.']
['Por fabor nota e reda neuronal ku ta generá kontesta na e preguntanan, ta spesialmente inakusá ora ta trata di kontenido numériko. Por ehèmpel, e kantidat di hende diagnostiká ku un malesa spesífiko.']
['Semper busca conseho di bo dokter of otro profesional di salud cualifica tocante un condicion medico. Nunca ignora conseho medico profesional of tarda pa busca esaki pa motibo di algo cu bo a lesa riba e website aki. Si bo ta kere cu bo por tin un emergencia medico, yama 911 of bay na e sala di emergencia mas cerca di bo mesora.']
['Copyright: Copyright']
['E Digital Millennium Copyright Act di 1998, 17 U.S.C. § 512 (e DMCA) ta duna derechi di rekurso pa doñonan di derechi di outor ku ta kere ku material ku ta aparesé riba internet ta violá nan derechi bou di lei di derechi di outor di Merka. ']
['Si bo ta kere di buena fe ku kualke kontenido òf material ku ta disponibel riba nos website òf servisio ta violá bo derechi di outor, abo (òf bo representante) por manda nos un notifikashon pa pidi pa kita e kontenido òf material òf pa blokia akseso na dje.']
["Mester manda e anunsio por eskrito via e-mail (wak e sekshon 'Kontacto' pa e-mail adrès)."]
['E DMCA ta eksigí ku bo notifikashon di violashon di derechi di outor ta inkluí e siguiente informashon: (1) deskripshon di e obra ku ta suheto di violashon; (2) deskripshon di e kontenido ku ta viola i informashon sufisiente pa nos por lokalisá e kontenido; (3) informashon di kontakto, inkluyendo bo adrès, number di telefòn i email; (4) un deklarashon di bo ku bo ta kere ku e kontenido no ta outorisá pa e doño di derechi di outor, su agente òf lei.']
['(5) un deklarashon di bo, firma bou di pena di huramentu falsu, ku e informashon den e notifikashon ta korekto i ku bo tin outoridat pa hasi uso di e derechonan di outor ku ta ser akusá di a wòrdu infringi;']
['i (6) un firma físiko òf elektróniko di e doño di derechi di outor òf un persona outorisá pa aktua na nòmber di e doño di derechi di outor.']
['Si bo no duna tur informashon ariba menshoná, e tratamentu di bo keho por tarda.']
['Kontakto']
['Por fabor manda nos un email ku kualke pregunta/sugerencia.']
What is pathophysiology of prostate cancer?
The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.
Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.
The prostate gland produces seminal fluid, which nourishes and transports sperm.
The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.
These include age, family history, race, and certain genetic mutations.
Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.
Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.
The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.
This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.
These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.
As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.
In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.
Once the cancer has spread, it can be more difficult to treat.
Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.
Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.
In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.
Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Tokante']
['BioMedLib ta usa kòmpiuter outomátiko (algoritmo di siñamentu di mashin) pa generá par di pregunta i kontesta.']
['Nos ta kuminsá ku 35 mion publikashon biomédico di PubMed/Medline. Tambe página di RefinedWeb.']
